Abstracts

A phase II study of weekly paclitaxel in patients with advanced or recurrent esophageal cancer who had previously received docetaxel-containing chemotherapy

Background Both docetaxel and paclitaxel are a class of microtubule-stabilizing anticancer agents. Partial cross-resistance between docetaxel and paclitaxel was indicate...

K. Yoshimura ;

Tomo Ando , MD;

K. Nakashima ;

H. Yoshita ;

M. Sakumura ;

M. Nomura ;

M. Muto ;

Y. Horie ;

H. Takeda ;

T. Yoshii ;

Y. Tahara ;

C. Katada ;

H. Ishikawa ;

A. Hosokawa ;

06/27/2022

Care delivery impact of the COVID-19 pandemic on anal cancer care

Background The ongoing COVID-19 pandemic has disrupted worldwide cancer care delivery, leading to a decline in cancer screening, delayed diagnostic tests, and treatment ...

06/27/2022

Safety and efficacy of GEMOX plus donafenib and tislelizumab as first-line therapy for advanced epithelial malignant biliary tract cancer

Background Nearly 70% of the newly diagnosed patients with malignant biliary tract cancer (BTC) are in advanced stage. Gemcitabine-based systemic chemotherapy is the sta...

06/27/2022

Increased risk of pancreatic cancer among 141,387 diabetic patients treated with DPP-4 inhibitors analyzed with common data model

Background DPP-4i are incretin-based anti-diabetes drugs which have been introduced recently. It is concerned that, however, that DPP-4i might cause pancreatic cancer or...

06/27/2022

Quality of life (QoL)-based end-points for patients with advanced pancreatic ductal adenocarcinoma (aPDAC): Results from the PanDA prospective observational study

Background Adequate design of clinical trials using QoL-based primary-end points to assess benefit derived from supportive interventions such as exercise, nutrition or c...

06/27/2022

Real-world dosing of regorafenib and outcomes among patients with metastatic colorectal cancer: A retrospective analysis using US claims data

Background Regorafenib is an oral multikinase inhibitor approved for advanced mCRC, advanced gastrointestinal stromal tumors, and advanced hepatocellular carcinoma. The ...

06/27/2022

Real-life experience with maintenance chemotherapy plus biologics after the first-line treatment of RAS wild-type metastatic colon cancer (mCRC): A multicenter Onco-Colon Turkey study

Background Randomized clinical trials showed that maintenance chemotherapy plus biologics in patients with mCRC could increase the progression free survival (PFS) withou...

O. Bozkurt ;

A. Bilici ;

M. Ozcelik ;

B. Oven ;

E. Simsek ;

C. Geredeli ;

T. Cil ;

H. Harputluoglu ;

H. Turk ;

U. Kefeli ;

A. Alacacioglu ;

D. Tural ;

Sevilay Şenol Çelik , PhD, RN;

M. Gumus ;

A. Sakin ;

M. Sendur ;

N. Karadurmus ;

M. Karaca ;

M. Artac ;

D. Cevik ;

E. Cubukcu ;

F. Dane ;

06/27/2022

The importance of maintenance chemotherapy in the first and second line of treatment of metastatic colorectal cancer

Background The first and second lines of CT are decisive in the treatment of colorectal cancer. Choosing the right one allows you to increase PFS and improve long-term r...

06/27/2022

The role of combined treatment of metastatic colorectal cancer in patients with liver metastases

Background Combined treatment for patients with metastatic colorectal cancer(mCRC) offers better long-term outcomes and chemotherapy can increase the rate of hepatic res...

06/27/2022

Circulating-tumour DNA (ctDNA) detection using an ultra-sensitive next generation sequencing (NGS)-based assay in patients with resected colorectal cancer (CRC) in the phase III ASCOLT trial

Background Identification of somatic mutations in ctDNA may detect minimal residual disease (MRD) in patients with curatively treated CRC who may eventually recur. Highl...

06/27/2022